The product of the human c-myc protoonco- 
It has been established that the product of the c-myc gene (Myc) is a short-lived nuclear phosphoprotein that has an important functional role during cellular proliferation, differentiation, and neoplasia (1) . The structural organization of Myc indicates the presence of subdomains that are found in several transcriptional regulators. A transcriptional activation region is located within the NH2-terminal domain (2) , and basic-helix-loop-helix (bHLH) and leucine zipper (Zip) motifs (associated with dimerization and DNA binding activities) are found within the COOH-terminal domain of Myc (1) . Furthermore, a specific DNA binding site for Myc has been identified as the E-box sequence CACGTG (3) (4) (5) (6) . These data suggest that Myc may function as a sequence-specific regulator of gene expression (7) .
The presence of dimerization motifs (HLH and Zip) in Myc suggests that this protein may function as a homo-or heterooligomer. A functional assay has failed to detect Myc homooligomers in intact cells (8) , but evidence for the formation of heterodimeric complexes of Myc with the bHLH/Zip protein Max has been obtained (9) . The overall structure of Max is similar to Myc, except that Max lacks the transcriptional activation domain that is present within the NH2-terminal region of Myc (9) (10) (11) . Significantly, the formation of MycMax heterodimeric complexes increases the specific binding of Myc to the DNA sequence CACGTG (9) (10) (11) (12) (13) . It is therefore likely that the Myc-Max complex represents the functional form of Myc in vivo (1) .
The Max protein has a long half-life and is expressed constitutively (9, 11) . In contrast, the expression of Myc is regulated at both transcriptional and posttranscriptional levels. An increase in Myc expression is observed during the growth factor-stimulated transition of growth-arrested cells from the Go to the G1 phase of the cell cycle (14) . However, in proliferating cells, the level of Myc expression is invariant during the cell cycle (15) . Therefore, Myc activity may be
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regulated by posttranslational modification in growing cells. The activity of many transcription factors is regulated by phosphorylation. For example, phosphorylation regulates the DNA binding activity of Myb, Max, SRF, Jun, E2F, and E4F (16) . Phosphorylation also regulates the transactivation of gene expression by cAMP response element binding protein (CREB) (17) and Jun (18) (19) (20) (24) were from D. Russell (University of Texas Southwestern Medical School). The plasmid pM21 containing the human c-myc gene (25) was obtained from C. V. Dang (Johns Hopkins University School of Medicine). The following plasmids were constructed:
(i) Point mutations were introduced at codons Thr-58 and Ser-62 by using PCR and the human c-myc gene (26) . The 526-bp Dra III-BstEII restriction fragments (containing the point mutations) were cloned into pM21 at the Dra III and BstEII sites. A simian virus 40 origin of DNA replication was cloned into these plasmids by replacing the murine leukemia virus long terminal repeat of pM21 (BamHI fragment) with the simian virus 40 promoter and origin of replication from pCMV2 (1064-bp BamHI fragment) to create pMyc.
(ii) The plasmid pG5ElbLuc was prepared from pG5E1bCAT (23) 2 ,ug of pUC13 carrier DNA) was included in the transfection (a total of 22 ,ug of DNA). The cells were harvested 36 hr posttransfection, and cell extracts were prepared for measurement ofluciferase and S3-galactosidase activity (27) .
Analysis of Metabolically Labeled Proteins. Metabolic labeling oftransfected cells in 100-mm dishes was performed 40 hr posttransfection by transferring the cells into culture medium (Flow Laboratories) supplemented with 1% fetal calf serum. The culture media used were (i) methionine-free modified Eagle's medium containing [35S]methionine (Amersham) at 200 ,uCi/ml (1 Ci = 37 GBq) or (ii) phosphate-free modified Eagle's medium containing [32P]phosphate (DuPont/NEN) at 2 mCi/ml. After 3 hr of additional incubation, the cells were lysed in 0.01 M Tris (pH 7.5), 0.05 M NaCl, 0.5% (vol/vol) Nonidet P-40, 0.5% (wt/vol) SDS, 0.5% (wt/vol) sodium deoxycholate, 1 mM phenylmethylsulfonyl fluoride, and leupeptin at 10 ,g/ml. The Myc proteins were immunoprecipitated with 10 ug of sheep anti-Myc IgG prebound to Pansorbin (Calbiochem) and resolved by SDS/ PAGE. The sheep anti-Myc IgG was purified from serum that was obtained after immunization with a bacterially expressed human Myc protein (residues 2-243) as an antigen (22) . Phosphopeptide mapping was performed by two-dimensional separation on 100-,um cellulose thin-layer plates (Machery & Nagel) as described (22) . Phosphoamino acid analysis was performed as described (22) .
Immunocytochemistry. Laser scanning confocal microscopy of cells stained with anti-Myc monoclonal antibody (Ab-2; 5 ,g/ml; Oncogene Sciences, Mineola, NY) and fluoroscein isothiocyanate-conjugated goat anti-mouse IgG antibody (ICN) was performed as described by Seth et al. (27) .
RESULTS
The DNA Sequence CACGTG Confers Myc Regulation of Gene Expression. To investigate the transactivation of gene expression by Myc, we used a reporter plasmid containing specific Myc DNA binding sites. The experimental strategy that we employed is illustrated schematically in Fig. 1 . A plasmid containing the firefly luciferase gene and a minimal Elb promoter (TATA) element was constructed. Transfection of this plasmid into CV-1 cells caused a very low level of luciferase activity (Fig. 2) . However, the insertion ofthe Myc binding site CACGTG into this plasmid ( Fig. 1 ) resulted in the observation of Myc-stimulated luciferase expression (Fig. 2) . Examination of the dose-response indicated that luciferase expression was increased in assays using 2 ,ug of the Myc expression vector and that 15 ,ug caused the maximum observed increase (data not shown). The level of Mycstimulated luciferase activity was increased when multiple binding sites were inserted into the reporter plasmid ( Fig.  2A) . However, the basal luciferase activity was also increased when a larger number of Myc binding sites were present in the reporter plasmid. [The increased basal activity is likely to be caused by endogenous E-box binding proteins (including Myc) present in CV-1 cells.] The fold increase in luciferase activity caused by Myc was similar when different numbers ofbinding sites (from one to four) were inserted into the reporter plasmid (Fig. 2B) (10) , also caused an inhibition of Mycstimulated luciferase activity (data not shown). An inhibition of a different function of Myc (rat embryo fibroblast transformation) caused by the expression of exogenous Max has previously been reported (13,-27) . It is likely that the observed inhibition of Myc function is the result of Max homodimers that compete with Myc complexes for binding to the DNA sequence CACGTG (1). Thus, the level of endogenous Max (9, 11) is likely to be sufficient to form complexes with Myc introduced into CV-1 cells (1). Therefore, in further experiments, we examined the transactivation function of Myc without expressing exogenous Max.
Myc Is Phosphorylated at Thr-58 and Ser-62 in Vivo. In previous studies we established that the Myc protein is phosphorylated in vitro at Ser-62 by MAP kinases (22, 23, 28) . Phosphorylation of Myc at this site in vivo has not been reported. However, we have investigated the phosphorylation ofthe Myc transactivation domain in intact cells by using a GAL4-Myc fusion protein (22) . Phosphoamino acid analysis and phosphopeptide mapping demonstrated that this fusion protein was phosphorylated at Ser-62 and at an additional Thr site. Mutational analysis demonstrated that the replacement of Ser-62 with Ala caused a decrease in the level of both Ser and Thr phosphorylation of the GAL4-Myc fusion protein (22) . We therefore examined the sequence surrounding the phosphorylation site at Ser-62 to identify possible Thr residues that could account for the observed Thr phosphorylation. It was noted that a single Thr residue was present in this region, Thr-58 (Fig. 3) (Fig. 4) . In addition, a major [32P]phosphopeptide was observed as a doublet (indicated with arrows) in maps of the wild-type Myc protein (Fig. 4) . We previously demonstrated in experiments using a GAL4-Myc fusion protein that this phosphopeptide doublet corresponds to partial and limit tryptic peptides containing the Myc sequence Phe-Glu-Leu-Leu-Pro-Thr-Pro-Pro-Leu-SerPro-Ser-Arg (residues 53-65) (22 (Fig. 4) . In contrast, the mutations at Thr-58 and Ser-62 did not cause marked changes in the phosphorylation ofMyc at other minor sites (Fig. 4) (Fig. 6B) . The observed punctate intranuclear localization (31) was found to be similar for the wild-type and the mutated Myc proteins (Fig. 6B) .
[Under these conditions, the low level of endogenous Myc was not detected in mock-transfected COS cells analyzed by immunoprecipitation and immunofluorescence (data not shown).] These data demonstrate that the reduced transactivation caused by the phosphorylation-defective Myc proteins (Fig. 5) is not accounted for by decreased expression or defective nuclear localization compared with wild-type Myc (Fig. 6) Thr-58 and Ser-62 were replaced with Glu. The transactivation by the mutant Myc proteins was similar to that caused by wild-type Myc (Fig. SB) . This result is in contrast to the observation of a marked reduction in Myc-stimulated gene expression caused by the replacement of Thr-58 and Ser-62 with Ala (Fig. 5A) . The lack ofa marked effect ofreplacement with Glu suggests that this acidic residue may partially mimic the effect of Myc phosphorylation. This observation is consistent with the hypothesis that Thr-58 and Ser-62 represent phosphorylation sites that regulate Myc function.
DISCUSSION
Mechanism of Phosphorylation of the Myc Transactivation Domain. One site of phosphorylation of the Myc transactivation domain, Ser-62 (Fig. 3) , is a substrate for MAP kinases in vitro (22) . It is therefore possible that MAP kinases may account for the phosphorylation of Ser-62 in vivo. The observation of MAP kinases in the nucleus of serumstimulated cells (22, 27, 37) is consistent with this hypothesis. However, it is possible that additional kinases may also contribute to the in vivo phosphorylation of Myc at [for example, cycin-dependent protein kinases (22, 23) and glycogen synthase kinase 3 (32) ]. Thus, the regulation of Ser-62 phosphorylation may be very complex, involving both growth factor-stimulated and cell cycle-regulated protein kinases.
We obtained evidence that, in addition to the phosphorylation of the Myc transactivation domain at Ser-62, one additional site of phosphorylation can be accounted for by Thr-58 (Fig. 3) . The primary sequence surrounding Thr-58 does not conform to the MAP kinase substrate consensus (28) , and in vitro phosphorylation of Myc at Thr-58 by MAP kinases is not observed (22) . Thus, the Thr-58 phosphorylation detected in intact cells must be accounted for by a protein kinase pathway distinct from MAP kinase. The results of mutational analysis suggest that there is an interaction between the phosphorylation sites Thr-58 and Ser-62 (Fig. 4) . One possibility that could account for this potential interaction is that Thr-58 is subjected to hierarchical phosphorylation (33) by a protein kinase such as glycogen synthase kinase 3 (34) . This hypothesis is supported by the observation of in vitro phosphorylation ofL-Myc within the conserved prolinerich NH2-terminal domain by glycogen synthase kinase 3 (32 (27) . Increased phosphorylation of Myc also occurs in growth factor-treated cells and may be cell cycle-dependent (22) . To investigate the role of this phosphorylation, we examined the effect of mutations at the phosphorylation sites located within the NH2-terminal transactivation domain of Myc. The replacement of Thr-58 and Ser-62 with Ala caused a marked inhibition of Mycstimulated gene expression (Fig. 5A) . Significantly, the introduction of negative charge at the phosphorylation sites by replacement of Thr-58 and Ser-62 with Glu caused Mycstimulated gene expression that was similar to that observed for wild-type Myc (Fig. 5B) (23) .
The regulation of the transactivation domain of Myc is similar to that reported for the transcription factors CREB (17) and Jun (18) (19) (20) . Mutation of Jun at the phosphorylation sites Ser-63 and Ser-73 (19, 20) caused an inhibition of transactivation of gene expression. However, the phosphorylation-defective Myc and Jun proteins are observed to exhibit a low basal transcriptional activity. This is distinct from the effect of CREB phosphorylation within the transactivation domain at Ser-133, which acts as a molecular switch to increase the transactivation function of CREB from an inactive state (17) .
Oncogenic Activity of Myc. Increased activity of the Myc protein has previously been associated with oncogenesis (1). It has been shown that the transactivation domain is required for cellular transformation by Myc (35) . Tumor formation may result from the activity of Myc as a transcription factor (1) . The 
